Arcutis Biotherapeutics(US:ARQT)2025-10-28 12:32Financial Performance - Q3 2025 net product revenue for ZORYVE was $99.2 million, a 122% increase compared to Q3 2024, and a 22% increase compared to Q2 2025[4] - ZORYVE net product sales for Q3 2025 were $99.2 million, driven by increasing demand and improved gross-to-net pricing[8] - Product revenue for Q3 2025 reached $99.219 million, a significant increase from $44.755 million in Q3 2024, representing a growth of 121%[27] - Total revenues for the nine months ended September 2025 were $246.569 million, compared to $125.182 million for the same period in 2024, marking a 97% increase[27] - Net income for Q3 2025 was $7.4 million, compared to a net loss of $41.5 million in Q3 2024[16] - Net income for Q3 2025 was $7.410 million, a recovery from a net loss of $41.537 million in Q3 2024[27] - Basic earnings per share for Q3 2025 were $0.06, compared to a loss of $0.33 per share in Q3 2024[27] Expenses - Research and development expenses for Q3 2025 were $19.6 million, consistent with the previous year[14] - Selling, general, and administrative expenses for Q3 2025 were $62.4 million, an increase from $58.8 million in Q3 2024[15] - Operating expenses for Q3 2025 totaled $90.693 million, up from $83.821 million in Q3 2024, reflecting an increase of 8%[27] - Research and development expenses for the nine months ended September 2025 were $56.600 million, down from $61.940 million in the same period of 2024, a decrease of 9%[27] - Selling, general, and administrative expenses increased to $62.404 million in Q3 2025 from $58.817 million in Q3 2024, an increase of 4%[27] - Interest expense for the nine months ended September 2025 was $9.082 million, down from $21.617 million in the same period of 2024, a reduction of 58%[27] - The company reported other income of $2.035 million in Q3 2025, compared to $4.182 million in Q3 2024, a decrease of 51%[27] Product Development - ZORYVE cream 0.05% received FDA approval for treating atopic dermatitis in children as young as 2 years old in October 2025[4] - The company provided initial 2026 full year net product sales guidance of $455–$470 million[17] - ZORYVE is projected to achieve peak sales of $2.6–$3.5 billion annually across current and potential future indications[7] - The company is preparing to initiate a Phase 1 study of ARQ-234, a potential biologic treatment for atopic dermatitis[9] Cash and Securities - Cash, cash equivalents, and marketable securities totaled $191.4 million as of September 30, 2025, down from $228.6 million at the end of 2024[16] - The weighted-average diluted shares used in computing earnings per share for Q3 2025 were 132,885 thousand, unchanged from Q3 2024[27]